The State accounts for over Rs 2,774 crores of the India's pharma market. "We have already launched operations in Southern India, Northern India and parts of Eastern India and plan to create a pan India presence for our products by January 2008. The launch in Maharashtra is aimed at helping us attain a total (domestic & international) turnover of Rs. 500 crore in the next 5 years. We are targeting a four fold increase in our turnover through a two pronged strategy of entry into domestic market and leveraging the export opportunity in contract manufacturing," said Ashwin Thacker, MD, Flamingo Pharma.

In Maharashtra, Flamingo is targeting a market share of 1 per cent on an annual basis. Flamingo plans to tap the retail market through a network of distributors along with a strong field staff of around 50 plus representatives. The company targets to have over 100 distributors and wholesalers to cover the Western India market. FPL's in-house state-of-the-art R & D unit at Taloja, recently got recognition from the Ministry of Science & Technology, Govt of India.

"Over the past 20 years, Flamingo has built a reputation for quality products in the global markets. We are happy to launch in India and in Maharashtra, as the domestic market is a huge opportunity and we would want to add value to the growing healthcare needs of this country. Anti-infectives, gastroenterological, orthocare, anti-allergics and nutritional products constitute over 72 per cent of the Indian pharma market, and the high-quality and affordable range of formulations from Flamingo is our contribution to make healthcare more accessible," Thacker said.